肺动脉内膜肉瘤1例并文献复习
Pulmonary Artery Intimal Sarcoma: A Case Report and Literature Review
DOI: 10.12677/ACM.2021.1111747, PDF, HTML, XML, 下载: 288  浏览: 440 
作者: 万甜甜, 栾琳慧, 丛金鹏, 陈云庆, 于文成*:青岛大学附属医院,山东 青岛
关键词: 肺动脉内膜肉瘤原发性Pulmonary Artery Intimal Sarcoma Primary
摘要: 目的:分析肺动脉内膜肉瘤临床特点,为临床诊治提供参考。方法:对1例青岛大学附属医院呼吸与危重症医科的肺动脉内膜肉瘤患者的临床资料进行回顾性分析,并且复习相关文献。结果:建议回当地医院治疗;方案:靶向药物安罗替尼,从小剂量开始;或:安罗替尼 + PD-1抑制剂;或:化疗:异环磷酰胺 + 顺铂。结论:肺动脉内膜肉瘤较为罕见,发病率低,易误诊为肺栓塞,且预后极差,本文旨在提高临床认识,以期早诊断,提高生存率。
Abstract: Objective: To analyze the clinical features of pulmonary artery intimal sarcoma and provide reference for clinical diagnosis and treatment. Methods: The clinical data of 1 patient with pulmonary endosarcoma in the Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Qingdao University were analyzed retrospectively, and the related literatures were reviewed. The results suggest returning to the local hospital for treatment; protocol: targeted drug anlotinib, starting from a small dose; or: anlotinib + PD-1 inhibitor; or: chemotherapy: ifosfamide + cisplatin. Conclusion: Pulmonary artery intimal sarcoma is rare, with low incidence, easy to be misdiagnosed as pulmonary embolism, and very poor prognosis. The purpose of this paper is to improve the clinical understanding in order to diagnose early and improve the survival rate.
文章引用:万甜甜, 栾琳慧, 丛金鹏, 陈云庆, 于文成. 肺动脉内膜肉瘤1例并文献复习[J]. 临床医学进展, 2021, 11(11): 5073-5078. https://doi.org/10.12677/ACM.2021.1111747

1. 引言

血管肉瘤是一种来源于血管内皮细胞或淋巴管内皮细胞的恶性软组织肿瘤,身体各个器官几乎均可发生,最常见的脏器包括心脏、肝脏以及乳腺,另外肺脏、脾脏、消化道、皮肤、骨骼、上颌窦、中枢神经系统、卵巢、阴道、肾上腺以及前列腺等也可发现。肺动脉内膜肉瘤(pulmonary artery intimal sarcoma, PAIS)是非常罕见地发生在肺循环大动脉壁的恶性间叶肿瘤,属于血管肉瘤中的一种。肺动脉内膜肉瘤临床表现无特异性,症状与肿瘤具体发生部位相关。本文患者已知情并同意报道。

2. 临床病例资料

患者,女,31岁,因“胸闷、胸痛2月”于2020-05-15入院。患者2月前无明显诱因开始出现胸闷憋气,活动后加重,休息后可缓解,伴有胸痛,位于前胸部,呈钝痛,深呼吸后加重,伴有咳嗽,干咳为主,无咳痰、咯血,无发热、盗汗,9天前于当地医院就诊,行肺CT检查提示见右肺多发片团状影,6天前于我院门诊就诊,完善胸部动态增强CT检查(图1)见纵隔、右肺门、右肺多发肿块并肺动脉主干、左右肺动脉及双肺动脉分支多发栓子形成,诊断为肺恶性肿瘤可能大,为进一步明确诊断收入院治疗。体格检查:T:37.0℃;P:72次/分;R:18次/分;BP:104/68 mmHg,神志清,精神可,口唇无紫绀,颈部及锁骨上未触及淋巴结肿大。双肺呼吸音清,未及啰音。心率72次/分,律齐,P2亢进,各瓣膜听诊区未闻及病理性杂音。实验室及辅助检查:血凝常规:D-二聚体700 ng/mL;血常规、肝肾功、血糖、电解质、女性肿瘤标记物、血气分析、心梗三项及二便常规分析 + 隐血试验结果大致正常。床旁心脏超声检查:1) 肺动脉占位性病变,肺动脉栓塞可能性大,栓子不排除肿瘤可能性,肺动脉高压(轻度),三尖瓣反流(轻度),肺动脉瓣反流(轻度);2) 二尖瓣反流(轻度);甲状腺超声检查:甲状腺左叶囊性小结节(TI-RADS2类);下肢血管超声、消化泌尿系统、妇科超声未见明显异常。PET/CT全身检查,结论:1) ① 右肺门区、双肺多发结节、团块,右肺为著,密度较低,边缘光滑,部分其内见充气支气管影,代谢轻度增高,SUVmax为4.1,考虑原发性肺肿瘤可能性大(肺间质来源?);② 纵隔内隆突下增大淋巴结,边界欠清,代谢轻度增高,SUVmax为2.6,考虑淋巴结转移可能;③ 双侧胸腔积液2) 双侧附件饱满,片状代谢增高,SUVmax为2.9。气管镜检查(图2),内镜所见:右中叶内侧支可见菜花样新生物,触之易出血,右下背段可见外压性狭窄,黏膜光滑,未见新生物、出血,右上及右下基底段各级支气管管腔通畅,黏膜光滑,未见新生物、出血。于右中叶新生物活检4次,并灌洗,局部喷洒凝血酶400 U,镜下未见活动性出血,出镜。活检病理结果:(右中叶新生物活检)少许肺组织及支气管粘膜呈慢性炎,间质纤维组织增生伴出血,其中一块粘膜下见少量圆形或卵圆形细胞伴间质粘液变性,考虑为肿瘤性病变。病变成分极少,无法准确分类。CT引导下行肺穿刺活检术,病理结果回报(右肺穿刺活检) (图3):梭形细胞肿瘤,间质粘液变,细胞有异型,意见为肉瘤,结合免疫组化及形态学,考虑肺动脉内膜肉瘤可能性大。免疫组化结果:CD31(−),ERG(−),SMA(+),MyoD1(−),Myogenin(−),Desmin(−),CD34(−),S100(−),INI-1(+),CKpan(−),EMA(−)。治疗:建议治疗方案:靶向药物安罗替尼,从小剂量开始;或:安罗替尼 + PD-1抑制剂;或:化疗:异环磷酰胺 + 顺铂。

Figure 1. There were multiple masses in the mediastinum, right hilum and right lung, and multiple emboli formation in the main pulmonary artery, left and right pulmonary arteries and branches of both pulmonary arteries

图1. 纵隔、右肺门、右肺多发肿块,肺动脉主干、左右肺动脉及双肺动脉分支多发栓子形成

Figure 2. Cauliflower-like neoplasm was observed in the medial branch of the right middle lobe, and an external pressure stenosis was observed in the right lower dorsal segment

图2. 右中叶内侧支可见菜花样新生物,右下背段可见外压性狭窄

Figure 3. Somatomedullary tumors, interstitial mucinous degeneration, and atypical cells were observed.HE2 200×

图3. 可见梭形细胞肿瘤,间质粘液变,细胞有异型,HE2 200×

3. 讨论

血管肉瘤是一种来源于血管内皮细胞或淋巴管内皮细胞的恶性软组织肿瘤,身体各个器官几乎均可发生,最常见的脏器包括心脏、肝脏以及乳腺,另外肺脏、脾脏、消化道、皮肤、骨骼、上颌窦、中枢神经系统、卵巢、阴道、肾上腺以及前列腺等也可发现 [1]。肺动脉内膜肉瘤(pulmonary artery intimal sarcoma, PAIS)是非常罕见地发生在肺循环大动脉壁的恶性间叶肿瘤,属于血管肉瘤中的一种 [2]。1923年,曼德尔斯塔姆通过尸检报告了第一例PAIS,到目前大约报道了有400例左右,大部分以病例报告的形式出现 [2] [3]。该病可发于各个年龄阶段,平均年龄大概在45~54岁,目前对其发病率与性别的关系尚存在争议 [3] [4]。肺动脉内膜肉瘤临床表现无特异性,最常见的症状是呼吸困难、胸背疼痛、咳嗽、咳血、体重减轻、发热等,腹泻为罕见首发症状,症状与肿瘤具体发生部位相关 [3] [5] [6]。PAIS易误诊为急性或慢性血栓栓塞,起源于肺动脉瓣的内膜肉瘤还可出现类似于慢性血栓栓塞性肺动脉高压 [5] [7]。

PAIS的鉴别诊断包括原发性或栓塞性血栓与原发性或栓塞性肿瘤。不太常见的可能性包括动脉瘤和假性动脉瘤。肺癌是最常见的原发性肿瘤。肺动脉中的栓塞性肿瘤现象可由乳腺癌、胃癌、肝癌、前列腺癌和肾癌引起。从影像学的角度来看,尽管晚期恶性疾病的CT表现可能具有特异性,但PAIS与血栓栓塞性疾病的鉴别诊断仍很困难。无肺栓塞的易感因素(彩色多普勒超声无下肢静脉血栓形成,无提示高凝状态的发现)和腔内充盈缺损患者在抗凝治疗后呼吸困难逐渐恶化是提示PAIS的因素。CT是鉴别PAIS和肺栓塞的第一步 [6]。提示PAIS的CT特征包括占据整个肺干腔的特殊充盈缺损,受累血管直径增大,CT血管造影时出现斑片状延迟增强,在静脉期更为明显。可进一步通过FDG-PET/CT的高摄取或对比增强MRI的高信号证实。经食管超声心动图、心脏磁共振成像(MRI)也被用于PAIS的诊断工作,并提供有关瓣膜和心室功能、病变的生理意义及其对心脏结构的影响 [6] [8] [9]。在PAIS和肺栓塞的鉴别诊断中,存在管腔外肿瘤扩展和远处转移是可靠的标志,但这些都是晚期癌症的表现 [8] [10] [11]。综上经胸和经食管超声心动图(TTE和TEE)、计算机断层扫描肺动脉造影(CTPA)、心脏磁共振成像(MRI)和氟脱氧葡萄糖正电子发射断层扫描/CT (FDG-PET/CT)对PAIS的诊断是必要的 [8] [12] [13] [14] [15]。对于严重呼吸困难和肺动脉充盈缺损且对抗凝治疗无反应的患者,应怀疑PAIS的可能,并结合CT和PET-CT进一步诊断。但确诊仍需要获取病理,可考虑使用支气管内超声(EBUS)引导的经支气管针吸(TBNA)来获取病理 [16],因多普勒超声探头显示血流实时图像,可对肺动脉完全闭塞没有血液流动的部位进行活检,这种部位的活检是相对是安全的。

PAIS的预后很差,最常见的死亡原因是由于右心室流出道阻塞所导致的心力衰竭,肿瘤栓子或相关血栓或邻近支气管侵犯引起的肺梗死可导致咯血。肿瘤通常转移到肺并可能栓塞,但也有转移到其他器官的报道,包括淋巴结、肝脏、胰腺、肾脏和肠系膜 [10] [17]。手术干预是PAIS的主要治疗手段,但术后预后不佳。据报道未经手术切除的患者中位生存时间为1.5个月 [12],而手术切除肿瘤可将生存时间延长至8~36个月 [5],因此早期和正确的诊断是建立适当治疗的必要条件。与单纯肿瘤切除相比,肺动脉内膜切除术(PEA)似乎有更高的生存率。在体外循环和深低温停循环的辅助下,PAS切除联合PEA可实现无转移病灶患者的最大肿瘤切除 [13]。理论上新辅助治疗可以使肿瘤缩小,提高可切除性,并可能中和微转移病灶,可能会提高生存率。有研究 [3] 在对391例PAIS确诊病例进行分析时,发现在综合成像的帮助下进行早期诊断,确定个体化手术策略联合辅助或新辅助化疗和/或放疗的多模式治疗可能会改善预后 [3] [5] [6] [8] [13] [18] [19]。但由于许多患者的血流动力学不稳定,无法耐受化疗/放疗的副作用。仍需要进一步的研究来评估放化疗在PAS中的作用和方案。唯一被批准用于软组织肉瘤的靶向药物是酪氨酸激酶制剂 [20] [21] [22],但尚未报道其用于PAIS。有研究提示患者在治疗子宫肌瘤过程中服用含有激素的药物导致病情急剧变化,这提示该肿瘤细胞可能具有激素敏感性,这有待进一步证实。由于搜索文献中报告的病例数量有限,PAIS治疗策略仍不清楚。

早期诊断,及早行手术切除,必要时可行放化疗治疗,能提高患者的生存时间。目前临床医师对于肺动脉内膜肉瘤的认识及基础研究不够,需要在未来做进一步的研究。

NOTES

*通讯作者Email: yuwencheng0@126.com

参考文献

[1] Lebellec, L., Defachelles, A.-S., Cren, P.-Y. and Penel, N. (2020) Maintenance Therapy and Drug Holiday in Sarcoma Patients: Systematic Review. Acta Oncologica, 59, 1084-1090.
https://doi.org/10.1080/0284186X.2020.1759825
[2] Blackmon, S.H. and Reardon, M.J. (2010) Pulmonary Artery Sarcoma. Methodist DeBakey Cardiovascular Journal, 6, 38-43.
https://doi.org/10.14797/mdcvj.219
[3] Bandyopadhyay, D., et al. (2016) Primary Pulmonary Artery Sarcoma: A Close Associate of Pulmonary Embolism-20-Year Observational Analysis. Journal of Thoracic Disease, 8, 2592-2601.
https://doi.org/10.21037/jtd.2016.08.89
[4] Chen, D., et al. (2016) Clinicopathological and Immunohistochemical Features of Pulmonary Artery Sarcoma: A Report of Three Cases and Review of the Literature. Oncology Letters, 11, 2820-2826.
https://doi.org/10.3892/ol.2016.4308
[5] Deng, L., et al. (2018) Clinical Presentation and Surgical Treatment of Primary Pulmonary Artery Sarcoma. Interactive Cardiovascular and Thoracic Surgery, 26, 243-247.
https://doi.org/10.1093/icvts/ivx318
[6] Chang, D.Y., et al. (2020) Pulmonary Artery Intimal Sarcoma: A Case Report and Literature Review. Respirology Case Reports, 8, e00530.
https://doi.org/10.1002/rcr2.530
[7] Furest, I., et al. (2006) Intimal Sarcoma of the Pulmonary Artery: A Rare Cause of Pulmonary Hypertension. Archivos de Bronconeumología, 42, 148-150.
https://doi.org/10.1157/13085566
[8] Attinà, D., et al. (2013) Pulmonary Artery Intimal Sarcoma. Problems in the Differential Diagnosis. La Radiologia Medica, 118, 1259-1268.
https://doi.org/10.1007/s11547-013-0943-x
[9] Pu, X., et al. (2018) Clinical and Radiological Features of Pulmonary Artery Sarcoma: A Report of Nine Cases. The Clinical Respiratory Journal, 12, 1820-1829.
https://doi.org/10.1111/crj.12743
[10] Austin, B.A. and Griffin, B.P. (2008) Pulmonary Artery Intimal Sarcoma: A Brief Case Series. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 21, 978.e5-978.e7.
https://doi.org/10.1016/j.echo.2007.10.013
[11] Yi, C.A., et al. (2004) Computed Tomography in Pulmonary Artery Sarcoma: Distinguishing Features from Pulmonary Embolic Disease. Journal of Computer Assisted Tomography, 28, 34-39.
https://doi.org/10.1097/00004728-200401000-00005
[12] Barmpas, A., et al. (2019) Intimal Sarcoma of the Pulmonary Artery, a Diagnostic Enigma. AME Case Reports, 3, 32.
https://doi.org/10.21037/acr.2019.07.02
[13] Han, Y., et al. (2021) Surgical Treatment of Primary Pulmonary Artery Sarcoma. General Thoracic and Cardiovascular Surgery, 69, 638-645.
https://doi.org/10.1007/s11748-020-01476-2
[14] Liu, M.X., et al. (2018) Differential Diagnosis of Pulmonary Artery Sarcoma and Central Chronic Pulmonary Thromboembolism Using CT and MR Images. Heart, Lung and Circulation, 27, 819-827.
https://doi.org/10.1016/j.hlc.2017.06.716
[15] Xi, X.Y., et al. (2019) Value of (18)F-FDG PET/CT in Differentiating Malignancy of Pulmonary Artery from Pulmonary Thromboembolism: A Cohort Study and Literature Review. The International Journal of Cardiovascular Imaging, 35, 1395-1403.
https://doi.org/10.1007/s10554-019-01553-5
[16] Al-Saffar, F., et al. (2015) Use of Endobronchial Ultrasound to Evaluate Nonthrombotic Endovascular Lesions in Pulmonary Arteries: A Systematic Review. Journal of Bronchology & Interventional Pulmonology, 22, 28-32.
https://doi.org/10.1097/LBR.0000000000000133
[17] Balduin, R., Drigo, R., Schiraldi, C. and Carraro, R. (1986) Ante Mortem Diagnosis of Primary Leiomyosarcoma of the Pulmonary Artery. Respiration, 49, 307-310.
https://doi.org/10.1159/000194896
[18] Blackmon, S.H., et al. (2009) Management of Primary Pulmonary Artery Sarcomas. The Annals of Thoracic Surgery, 87, 977-984.
https://doi.org/10.1016/j.athoracsur.2008.08.018
[19] Sejben, A., et al. (2020) Intimal Sarcoma of Pulmonary Arteries. Orvosi Hetilap, 161, 232-236.
https://doi.org/10.1556/650.2020.31642
[20] Van der Graaf, W.T., et al. (2012) Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet, 379, 1879-1886.
https://doi.org/10.1016/S0140-6736(12)60651-5
[21] Lee, Y., et al. (2016) Clinical Characteristics and Treatment Outcomes of Primary Pulmonary Artery Sarcoma in Korea. Journal of Korean Medical Science, 31, 1755-1760.
https://doi.org/10.3346/jkms.2016.31.11.1755
[22] Srivali, N., Yi, E.S. and Ryu, J.H. (2017) Pulmonary Artery Sarcoma Mimicking Pulmonary Embolism: A Case Series. QJM, 110, 283-286.
https://doi.org/10.1093/qjmed/hcw232